CA3112808A1 - Systeme d'administration transdermique de medicament - Google Patents

Systeme d'administration transdermique de medicament Download PDF

Info

Publication number
CA3112808A1
CA3112808A1 CA3112808A CA3112808A CA3112808A1 CA 3112808 A1 CA3112808 A1 CA 3112808A1 CA 3112808 A CA3112808 A CA 3112808A CA 3112808 A CA3112808 A CA 3112808A CA 3112808 A1 CA3112808 A1 CA 3112808A1
Authority
CA
Canada
Prior art keywords
formulation
basement membrane
active ingredient
agent
penetration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3112808A
Other languages
English (en)
Inventor
John J. Masiz
Zhen Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biophysics Pharma Inc
Original Assignee
Biophysics Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biophysics Pharma Inc filed Critical Biophysics Pharma Inc
Publication of CA3112808A1 publication Critical patent/CA3112808A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Abstract

La présente invention concerne des systèmes, des méthodes et des kits d'administration transdermique qui comprennent un agent qui permet de pénétrer dans la membrane basale, une membrane de la peau auparavant décrite comme difficile à pénétrer. En particulier, la formulation comprend un perturbateur de la membrane basale qui dénature de manière réversible la membrane basale de la peau. La formulation de la présente invention comprend en outre au moins un agent de pénétration, au moins un vaso-modulateur et au moins un principe actif. Dans un mode de réalisation, l'agent de pénétration comprend un solvant, un agent lipophile, un agent hydrophile, le perturbateur de la membrane basale, le modulateur vasculaire et le principe actif passant à travers la couche cornée et l'épiderme. Le perturbateur de la membrane basale permet au modulateur vasculaire et au principe actif de passer à travers la membrane basale afin de pénétrer dans le derme. Le principe actif, une fois au niveau du derme, est administré localement au tissu ou de façon systémique au flux sanguin.
CA3112808A 2018-09-27 2019-09-25 Systeme d'administration transdermique de medicament Pending CA3112808A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862737479P 2018-09-27 2018-09-27
US62/737,479 2018-09-27
US16/582,922 2019-09-25
PCT/US2019/053000 WO2020069013A1 (fr) 2018-09-27 2019-09-25 Système d'administration transdermique de médicament
US16/582,922 US11446257B2 (en) 2018-09-27 2019-09-25 Transdermal drug delivery system

Publications (1)

Publication Number Publication Date
CA3112808A1 true CA3112808A1 (fr) 2020-04-02

Family

ID=69947952

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3112808A Pending CA3112808A1 (fr) 2018-09-27 2019-09-25 Systeme d'administration transdermique de medicament

Country Status (5)

Country Link
US (3) US11446257B2 (fr)
AU (1) AU2019349935B2 (fr)
CA (1) CA3112808A1 (fr)
MX (1) MX2021002833A (fr)
WO (1) WO2020069013A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112808A1 (fr) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Systeme d'administration transdermique de medicament
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903159A (en) 1970-09-17 1975-09-02 Armour Pharma Methanesulfonamidophenyl guanidine compounds
JPH09501414A (ja) 1993-06-23 1997-02-10 ジョン ジェイ． マシズ 分子経皮搬送方式
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5460821A (en) * 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
CA2177081A1 (fr) 1993-11-23 1995-06-01 Graham J. Durant Guanidines substituees a usage therapeutique
EP0751767A4 (fr) 1994-02-03 1997-12-10 Cambridge Neuroscience Inc Guanidines therapeutiques
US7351743B1 (en) 1994-02-03 2008-04-01 Wyeth Therapeutic guanidines
ES2284250T3 (es) 1998-04-21 2007-11-01 Infectio Recherche Inc. Formulaciones para la prevencion o el tratamiento de enfermedades que afectan a la membrana mucosa o la piel, o para la prevencion del embarazo.
US6611707B1 (en) 1999-06-04 2003-08-26 Georgia Tech Research Corporation Microneedle drug delivery device
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6914051B1 (en) * 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
EP1461084A2 (fr) 2001-12-11 2004-09-29 The Board Of Trustees Of The Leland Stanford Junior University Reactifs pour le transport de guanidinium et conjugues associes
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20060013866A1 (en) 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US20060062836A1 (en) * 2004-09-21 2006-03-23 Carter Stephen G Methods of device-assisted drug delivery
US20080319092A1 (en) 2005-08-05 2008-12-25 Nuvo Research Inc. Transdermal Drug Delivery Formulation
US9427419B2 (en) 2005-09-12 2016-08-30 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (DMSO)
US7700565B2 (en) 2005-09-23 2010-04-20 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
WO2007038172A2 (fr) 2005-09-23 2007-04-05 Nitto Denko Corporation Vecteurs d'apport de guanidinium
US20070185216A1 (en) * 2006-02-09 2007-08-09 Marcia Snyder Antiviral method
US9642912B2 (en) * 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
US8343486B2 (en) 2008-01-22 2013-01-01 Biochemics, Inc. Methods and compositions for topical treatment of medical conditions including wounds and inflammation
WO2009152372A1 (fr) 2008-06-11 2009-12-17 Biochemics, Inc. Contrôle de la physiologie des vaisseaux sanguins pour le traitement de troubles cutanés
US9724278B2 (en) 2008-06-13 2017-08-08 Colgate-Palmolive Company Oral compositions and uses thereof
CA2749941C (fr) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofene destine a etre administre de maniere topique
US9566256B2 (en) 2008-09-22 2017-02-14 Biochemics, Inc. Transdermal drug delivery using an osmolyte and vasoactive agent
EP2352543B1 (fr) 2008-12-04 2019-04-03 BioChemics, Inc. Procédés et compositions pour un retrait de tatouage
JP5947721B2 (ja) 2009-10-30 2016-07-06 アベラ ファーマスーティカルズ インコーポレイテッド 変形性関節症を治療するためのジメチルスルホキシド（ｄｍｓｏ）およびメチルスルホニルメタン（ｍｓｍ）製剤
GB2481630A (en) 2010-07-01 2012-01-04 Robert Taylor Composition for dental health
EP2546244A1 (fr) 2011-07-13 2013-01-16 Koste Biochemicals Procédé supercritique de fabrication d'ambradiol, de sclaréolide et (-)-ambrafuran à partir de sclaréol
WO2014144712A1 (fr) * 2013-03-15 2014-09-18 Biochemics, Inc. Formulations topiques et méthodes d'administration de médicament
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
WO2016068336A1 (fr) 2014-10-30 2016-05-06 旭化成ケミカルズ株式会社 Agent et agent auxiliaire de promotion d'absorption transdermique
LT3265140T (lt) 2015-03-02 2021-09-27 Medlab Clinical U.S., Inc. Transmukozinės ir transderminės pristatymo sistemos
WO2017083637A1 (fr) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Oligophosphotriesters riches en guanidinium à pénétration cellulaire pour l'administration de médicament et de sonde
AU2017210319A1 (en) 2016-01-20 2018-08-23 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
WO2018213071A1 (fr) 2017-05-15 2018-11-22 Biochemics, Inc. Polythérapie administrée par voie transdermique pour le traitement de la douleur
CA3112808A1 (fr) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Systeme d'administration transdermique de medicament
CA3168441A1 (fr) 2020-02-20 2021-08-26 North Atlantic Holdings LLC Systeme d'administration transmucosale de medicaments

Also Published As

Publication number Publication date
AU2019349935B2 (en) 2023-01-12
AU2019349935A1 (en) 2021-03-18
US20220387343A1 (en) 2022-12-08
MX2021002833A (es) 2021-05-27
BR112021003746A2 (pt) 2021-05-25
US11865217B2 (en) 2024-01-09
US20200101025A1 (en) 2020-04-02
WO2020069013A1 (fr) 2020-04-02
US11446257B2 (en) 2022-09-20
US20240108588A1 (en) 2024-04-04

Similar Documents

Publication Publication Date Title
US10537536B2 (en) Transdermal drug delivery using an osmolyte and vasoactive agent
US11865217B2 (en) Transdermal drug delivery system
US9675562B2 (en) Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
ES2445443T3 (es) Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma
US5652256A (en) Topical composition for fungal treatment
CA3049389A1 (fr) Formulations topiques de detomidine
US20160058725A1 (en) Topical Formulations and Methods for Drug Delivery
US20210259951A1 (en) Transmucosal Drug Delivery System
CN113056268A (zh) 纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途
EP3856140A1 (fr) Système d'administration transdermique de médicament
BR112021003746B1 (pt) Formulação para distribuição transdérmica de um ingrediente ativo a um mamífero, e kit
CN113056269A (zh) 纤溶酶原激活物抑制剂1(pai-1)抑制剂的用途
US20210177740A1 (en) Transpore delivery of cannabinoid and uses thereof
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928

EEER Examination request

Effective date: 20220928